Skip to Content
COVID-19 Resources
Cancer Imaging Program (CIP)
Contact CIP
Show menu
Search this site
Last Updated: 10/28/16

Newsletter No. 88 — June 2006

NIH - New Funding Initiatives

1. Exploratory/Developmental Bioengineering Research Grants(EBRG) [R21] (PA-06-418) (Multiple ICs)
Application Receipt/Submission Date(s): Multiple Dates, see announcement.
The EBRG can support: 1) innovative, high-risk, high pay-off projects; 2) exploration of new approaches or concepts to a particular substantive area; 3) research and development of new technologies, techniques or methods; or 4) initial research and development of data upon which significant future research may be built. In keeping with the intent of the R21 program, in all four instances above, there may or may not be any preliminary results. The R21 mechanism is intended to encourage new exploratory and developmental research projects.

2. Bioengineering Research Grants (BRG) [R01] (PA-06-419) (Multiple ICs)
Application Receipt/Submission Date(s): Multiple dates, see announcement.
Bioengineering integrates principles from a diversity of technical and biomedical fields, and the resulting multi-disciplinary research is providing new basic understandings, novel products, and innovative technologies that improve basic knowledge, human health, and quality of life. Bioengineering also crosses the boundaries of scientific disciplines that are represented throughout academia, Federal laboratories, and industry. Solicited here, under the auspices of BECON, are grant applications that propose bioengineering research projects that serve the mission of one or more of the participating NIH institutes or centers.

3. Innovations in Biomedical Computational Science and Technology (R01) (PAR-06-410) (Multiple ICs)
Application Receipt/Submission Date(s): June 24, 2006; September 24, 2006; January 24, 2007; May 24, 2007; September 24, 2007; January 24, 2008; May 24, 2008; September 24, 2008, January 24, 2009
Projects must span the interface of biomedical research and biomedical computational science and technology. Applicants will be expected to demonstrate fundamental understanding and adequate expertise in both the relevant areas of computational science and technology and biomedical research. Cross-disciplinary collaborations are strongly encouraged, including those which have been initiated or fostered through other cross-cutting initiatives, and now are seeking independent support.

4. Exploratory Innovations in Biomedical Computational Science and Technology (R21) (PAR-06-411) (Multiple ICs)
Application Receipt/Submission Date(s): June 24, 2006; September 24, 2006; January 24, 2007; May 24, 2007; September 24, 2007; January 24, 2008; May 24, 2008; September 24, 2008, January 24, 2009
See above to PAR-06-410.

5. Quick-Trials for Novel Cancer Therapies: Exploratory Grants (R21) (PAR-06-451)
Application Receipt/Submission Date(s): August 9, 2006; December 9, 2006; April 9, 2007; August 9, 2007; December 9, 2007
The focus of this QUICK-TRIAL FOA is on translational research in new agent development to ensure the timely exploitation of new cancer therapeutic approaches, including the development of new cancer prevention agents. QUICK-TRIAL applications do not require extensive preliminary data in the grant application and support exploratory translational and clinical research studies involving cancer prevention, chemotherapy, and rapid development and application of novel clinical cancer therapies, including image-guided therapeutic procedures.

6. Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grants (T32) (PA-06-468)
Application Receipt/Submission Date(s): Multiple dates, see announcement.
The objective of the NRSA program is to provide predoctoral and postdoctoral research training opportunities for individuals interested in pursuing research careers in biomedical, behavioral and clinical research. Each NIH Institute and Center has a unique scientific purview and different program goals and initiatives that evolve over time. It is therefore critical that all applicants consult with the scientific/research contact at the relevant NIH Institute or Center for current information about program priorities and policies before preparing an application.

7. Bioengineering Research Partnerships (BRP) [R01] (PAR-06-459)(Multiple ICs)
Letter of intent receipt dates: August 20 and December 20, 2006
Application Receipt/Submission Date(s): September 20, 2006 and January 22, 2007
The primary objective of this program announcement is to encourage basic, applied, and translational bioengineering research that could make a significant contribution to improving human health. A second objective is to encourage collaborations and partnerships among the allied quantitative and biomedical disciplines. A BRP must bring together the necessary physical, engineering, and computational science expertise with biological or clinical expertise and resources to address a significant area of bioengineering research within the mission of the NIH.

8. NIH Offers Commercialization Assistance Program to SBIR Phase II Awardees (NOT-OD-06-081)
The CAP consists of training workshops, individual mentoring and consulting sessions, and it culminates with an opportunity for companies to present their business opportunities to potential investors and strategic partners at the NIH Life Sciences Showcase. Participation is free; however, selected participants are responsible for their travel expenses to attend two required workshops and the optional showcase. Detailed program information, eligibility requirements, and application instructions are available at The deadline for submitting an application is July 31, 2006. Approximately 125 companies will be selected to participate in this year’s NIH CAP and will be notified by August 14, 2006.

9. Nanoscience and Nanotechnology in Biology and Medicine(R21) (PAR-06-475) (Multiple ICs)
Application Receipt/Submission Date(s): August 18, 2006
This funding opportunity announcement (FOA) is aimed at enhancing nanoscience and nanotechnology research approaches that have the potential to make valuable contributions to biology and medicine. The purpose of this initiative is to stimulate cross-cutting, integrative research in these fields of science and technology. In particular, this initiative invites research on: i) the creation and use of structures, devices and systems that have novel properties and functions because of their small size, that may be used to achieve a fundamental understanding of biological processes and /or contribute to disease detection, therapy, or prevention; ii) conception and fabrication of devices, that will effectively detect and analyze nanoscale entities of relevance to biomedicine; and iii) the study of biological systems at the nanoscale for the explicit purpose of using that information to develop nanotechnologies and nanostructured materials that will in turn benefit biology and medicine. Tthe research projects that will be most responsive to this FOA will require interdisciplinary collaborations among investigators with expertise in a range of disciplines, including but not limited to engineering, physics, chemistry, cellular and molecular biology, materials and computer science. Applications submitted in response to this PA may propose hypothesis-driven, discovery-driven, developmental, or design-directed research.


Consensus Recommendations for the Use of 18F-FDG PET as an Indicator of Therapeutic Response in Patients in National Cancer Institute Trials, Shankar LK, Hoffman JM, Bacharach S, Graham MM, et al. J Nucl Med (2006) 47:1059-1066. See Clinical Guidelines.

CIP Cancer Tracer Synthesis Resources
The Cancer Imaging Program has been creating Investigational New Drug Applications (IND) for imaging agents in order to engage in multi-center clinical trials of these materials. A subset of the documents filed is being made available to the research community to implement routine synthesis of tracers at their own facilities and to assist investigators with the filing of their own INDs. The first of these document sets is for F-18 fluorothymidine (FLT).

NIH/AHRQ to Update/Post FOAs with New SF424 (R&R) and PHS 398 Electronic Forms (NOT-OD-06-078)
Release Date: June 22, 2006 and NIH/AHRQ recently have made changes to the standard SF424 (R&R) and agency-specific PHS 398 electronic form components used for the electronic submission of grant applications. The forms changes provide greater consistency between forms and align the forms with current policy.

NIH Extramural Nexus
The NIH Extramural Nexus is a bimonthly update from the NIH Office of Extramural Research (OER), NIH. The OER is the hub for grants policy and operations, grants administration, and the coordination of NIH’s extramural programs and activities. See the issues.

Interagency Council on Biomedical Imaging in Oncology Meeting
The next ICBIO meeting is Tuesday, October 17, 2006, from 8:30 AM in EPN, at 6130 Executive Boulevard, Rockville, MD. The deadline for submission is August 31, 2006. See for details.

The Cancer Imaging Program of the NCI requests submissions for its Development of Clinical Imaging Drugs and Enhancers (DCIDE) initiative. The goal is the rapid movement of promising, novel cancer imaging enhancers or molecular probes from the laboratory to proof of principle clinical trials. See the web site for details. URL:

The NIH Commons web site allows all NIH grantee organizations to interact with grants data, to check the status of grant applications, including viewing scores and summary statements when they are ready, and to submit progress reports on line, among a number of functions. Applicants and grants administrators should become familiar with the Commons.


Hilton Waikoloa Village, Hawaii, Hawaii, August 30-September 2, 2006

September 14 - 15, 2006, Gaithersburg, Maryland

Fifth Inter-Institute Workshop on OPTICAL DIAGNOSTIC IMAGING FROM BENCH TO BEDSIDE at the National Institutes of Health
25-27 September 2006
Natcher Auditorium, National Institutes of Health
Bethesda, Maryland USA

November 13-15, 2006, Vienna, Austria. Organized by the International Atomic Energy Agency

RSNA 2006
November 26 - December 1, 2006, McCormick Place, Chicago, IL
CIP 10th Anniversary Celebration Events:
Lecture Series on Cancer Imaging Clinical Trials, Image-Guided Intervention, and Quantitation for Change Analysis
Lakeside Learning Center, Molecular Imaging Zone
Technical Exhibit in Hall A, South Building, Booth 1043

April 30 - May 4, 2007, Aachen, Germany

The Cancer Imaging Program at NCI has created this e-mail distribution list to notify interested people about funding opportunities and other issues related to imaging research. Its primary purpose is to call your attention to important, relevant information on NIH Web pages, or in the NIH Guide. Occasionally it may be used to clarify areas of confusion, or disseminate answers to frequently asked questions.

If you wish to remain on the list, no action is necessary. If you wish to be added to the list, please contact Dr Barbara Croft by return e-mail ( Please include your complete mailing address, title, phone and fax numbers.

Cancer Imaging Program
Division of Cancer Treatment and Diagnosis, NCI
6130 Executive Boulevard - MSC-7412
Bethesda, MD 20892-7412
Tel: 301 496 9531
Fax: 301 480 3507